New partnership aims to improve antibiotic access in low-resource nations

The article reports on the new agreement between the Global Antibiotic Research and Development Partnership (GARDP) and the Stop TB Partnership's Global Drug Facility (GDF), announced in May, which aims to coordinate efforts in addressing access and pricing issues of antibiotics in LMICs. 

Bringing context to partnership and the AMR crisis, the article references the most recent report to come out of the Foundation’s Antimicrobial Resistance Programme, which found that the pharmaceutical companies developing critical new antimicrobial products do not have adequate plans in place to ensure their products will be available in LMICs.  

The article also cites that among all five antimicrobial products included in the scope of the Foundation’s report, concrete commitments for product registration were only identified in five LMICs. 

“In order to ensure sustainable access to antibiotics for patients worldwide, partnerships and tailored approaches are necessary, especially for low- and middle-income countries,” Marijn Verhoef, Director of Operations and Research at the Access to Medicine Foundation, told CIDRAP. “We need more of these critical partners to work together to curb AMR.”